Q-omics provides the consensus-scored ZBTB46 profile across patient tissues and cancer cell-line models. ZBTB46 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB46 is differentially expressed in 13, with the highest sampling consensus in UCEC. Additionally, ZBTB46 RNA expression shows 19,240 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, UCEC, and UVM as cancer lineages where ZBTB46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB46 survival associations across molecular data types. ZBTB46 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB46 RNA expression–survival associations across cancer types. High ZBTB46 expression shows unfavorable associations in LUSC, KIRP and LUAD, but favorable associations in KIRC, CESC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB46 RNA expression.
This table summarizes ZBTB46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB46 shows lower tumor expression in UCEC, KICH, KIRP and LUSC and higher tumor expression in STAD and HNSC. The UCEC box plot shows higher ZBTB46 RNA expression in normal versus tumor tissue (log2 FC = −1.832, t-test p < 0.001).
This table shows molecular features associated with ZBTB46 in patient tissues and cancer cell lines. In patient samples, ZBTB46 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
